A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (SOLARIS)

Study Title
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia (SOLARIS)
Teva Identifier
TV44749-CNS-30096
ClinicalTrials.gov Identifier
NCT05693935
Study Status
Completed
Trial Condition(s)
Schizophrenia
Interventions
Drug: TV-44749 | Drug: Placebo
EudraCT Number
2022-001865-11
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
disease-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult
Age Range
18 Years to 64 Years
Trial Duration
January 24, 2023 - January 27, 2025
Phase
Phase 3

Additional info

Study Type

Interventional